Targeting cdc25c, plk1 and chek1 to overcome docetaxel

HIGHLIGHTS

• who: Top from the Department of Pathology, HistoCytoPathology Unit, Translational Research Laboratory and Biobank, RoussyUniversity Paris-Sud, France have published the paper: Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel, in the Journal: (JOURNAL)
• what: The authors focused on the role of the cell cycle regulator which was under-expressed in the Docetaxel-resistant cell lines its inhibition resulting from the promoter methylation. The authors focused on the molecular mechanisms of Docetaxel resistance to identify relevant therapeutic targets to overcome this resistance. The authors report that LZTS1 is inhibited by methylation of its promoter in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.